Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine

Infection and Immunity

Volumn 74, Issue 10, 2006, Pages 5820-5825

  Bhattacharjee, Apurba K ^a   Izadjoo, Mina J ^b   Zollinger, Wendell D ^a   Nikolich, Mikeljon P ^a   Hoover, David L ^a,c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c Clinical Research Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BRUCELLA VACCINE; OUTER MEMBRANE PROTEIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIUM CULTURE; BIOLOGICAL WARFARE; BRUCELLA MELITENSIS; BRUCELLOSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; LIVER; LUNG; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SERUM; SPLEEN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ANIMALS; BRUCELLA MELITENSIS; BRUCELLA VACCINE; BRUCELLOSIS; IMMUNIZATION; LIPOPOLYSACCHARIDES; LIVER; LUNG; MICE; MICE, INBRED BALB C; PORINS; SPLEEN; VACCINATION; VACCINES, SUBUNIT;

EID: 33749236471     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00331-06     Document Type: Article

References (35)

1. Al-Mariri, A., A. Tiber, P. Mertens, X. D. Bolle, P. Mitchel, J. Godefroid, K. Walravens, and J. J. Letesson. 2001. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant protein with CpG oligodeoxynucleotide as adjuvant. Infect. Immun. 69:4816-4822.
2. Bhattacharjee, A. K., L. L. Van De Verg, M. J. Izadjoo, L. Yuan, T. L. Hadfield, W. D. Zollinger, and D. L. Hoover. 2002. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a non-covalent complex with Neisseria meningitidis group B outer membrane protein. Infect. Immun. 70:3324-3329.
3. Blasco, J. M., and R. Diaz. 1993. Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 342:805.
4. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, et al. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13:821-829.
5. Bundle, D. R., J. W. Cherwonogrodzky, and M. Perry. 1987. Structural elucidation of the Brucella melitensis M antigen by high resolution NMR at 500 MHz. Biochemistry 26:8717-8726.
6. Chang, M., M. K. Glynn, and S. L. Groseclose. 2003. Endemic notifiable bio-terrorism-related diseases, United States, 1992-1999. Emerg. Infect. Dis. 9:556-564.
7. Cloeckaert, A., M. S. Zygmunt, G. Dubray, and J. N. Limet. 1993. Characterization of O-polysaccharide-specific monoclonal antibodies derived from mice infected with the rough Brucella melitensis strain B115. J. Gen. Microbiol. 139:1551-1556.
8. Cloeckaert, A., I. Jacques, P. de Wergifosse, G. Dubray, and J. N. Limet. 1992. Protection against Brucella melitensis and Brucella abortus in mice with immunoglobulin G (IgG), IgA, and IgM monoclonal antibodies specific for a common epitope shared by the Brucella A and M smooth lipopolysaccharide. Infect. Immun. 60:312-315.
9. Crawford, R. M., L. L. Van De Verg, L. Yuan, T. L. Hadfield, R. L. Warren, E. S. Drazek, H. H. Houng, C. Hammack, K. Sasala, T. Polsinelli, J. Thompson, and D. L. Hoover. 1996. Deletion of purE attenuates Brucella melitensis infection in mice. Infect. Immun. 64:2188-2192.
10. Edmonds, M. D., A. Cloeckaert, and P. H. Elzer. 2002. Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Vet. Microbiol. 88:205-221.
11. Elberg, S. S. 1973. Immunity to brucella infection. Medicine (Baltimore) 52:339-356.
12. Elzer, P. H., F. M. Enright, J. R. McQuiston, S. M. Boyle, and G. G. Schurig. 1998. Evaluation of a rough mutant of Brucella melitensis in pregnant goats. Res. Vet. Sci. 64:259-260.
13. Engvall, E., and P. Perlmann. 1972. Enzyme-linked immunosorbent assay. ELISA III. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen coated tubes. J. Immunol. 109:129-135.
14. Goldstein, J., T. Hoffman, C. Frasch, E. F. Lizzio, P. R. Beining, D. Hochstein, Y. L. Lee, R. D. Angus, and B. Golding. 1992. Lipopolysaccharide from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus as a carrier in vaccines. Infect. Immun. 60:1385-1389.
15. Hoover, D. L., M. P. Nikolich, M. J. Izadjoo, R. H. Borschel, and A. K. Bhattacharjee. 2004. Development of new Brucella vaccines by molecular methods, p. 368-402. In I. Lopez-Goni and I. Moriyon (ed.), Brucella: molecular and cellular biology. Horizon Scientific Press, Wymondham, United Kingdom.
16. Hoover, D. L., R. M. Crawford, L. L. Van De Verg, M. J. Izadjoo, A. K. Bhattacharjee, C. M. Paranavitana, R. L. Warren, M. P. Nikolich, and T. L. Hadfield. 1999. Protection of mice against brucellosis by vaccination with Brucella melitensis 16M (ΔpurEK). Infect. Immun. 67:5877-5884.
17. Izadjoo, M. J., Y. Polotsky, M. G. Mense, A. K. Bhattacharjee, C. M. Paranavitana, T. L. Hadfield, and D. L. Hoover. 2000. Impaired control of Brucella melitensis infection in Rag1-deficient mice. Infect. Immun. 68:5314-5320.
18. Jacques, I., V. Olivier-Bernardin, and G. Dubray. 1991. Induction of antibody and protective responses in mice by Brucella O-polysaccharide-BSA conjugate. Vaccine 9:896-900.
19. Lowell, H. G., W. R. Ballou, L. F. Smith, A. Wirtz, W. D. Zollinger, and W. T. Hochmeyer. 1988. Proteosome-lipopeptide vaccine: enhancement of immunogenicity for malaria CS peptides. Science 240:800-802.
20. McQuiston, J. R., R. Vemulapalli, T. J. Inzana, G. G. Schurig, N. Sriranganathan, D. Fritzinger, T. L. Hadfield, R. A. Warren, L. E. Lindler, N. Spellings, D. Hoover, S. M. Halling, and S. M. Boyle. 1999. Genetic characterization of a Tn5-disrupted glycosyltransferase gene homolog in Brucella abortus and its effect on lipopolysaccharide composition and virulence. Infect. Immun. 67:3830-3835.
21. Mense, M. G., L. L. Van De Verg, A. K. Bhattacharjee, J. L. Ruckert, J. A. Hart, L. E. Lindler, T. L. Hadfield, and D. L. Hoover. 2000. Bacteriological and histopathological features of a mouse model for intranasal Brucella melitensis infection. Am. J. Vet. Res. 61:715-721.
22. Neely, A. N., A. K. Bhattacharjee, G. F. Babcock, I. A. Holder, and A. S. Cross. 2002. Differential effects of two different routes of immunization on protection against Gram-negative sepsis by a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine in a burned mouse model. J. Burn Care Rehabil. 23:333-340.
23. Oliveira, S. C., and G. A. Splitter. 1996. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14:959-962.
24. Pappagianis, D., S. S. Elberg, and D. Crouch. 1966. Immunization against Brucella infections. Effects of graded doses of viable attenuated Brucella melitensis in humans. Am. J. Epidemiol. 84:21-31.
25. Perez-Meglosa, M., H. D. Ochs, P. S. Linsley, J. D. Laman, M. Van Meurs, R. A. Flavell, R. K. Ernst, S. I. Miller, and C. B. Wilson. 2001. Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine. Eur. J. Immunol. 31:2373-2381.
26. Robertson, G. T., and R. Roop. 1999. The Brucella abortus host factor I (HF-I) protein contributes to stress resistance during stationary phase and is a major determinant of virulence in mice. Mol. Microbiol. 34:690-700.
27. Rotz, L. D., A. S. Khan, S. R. Lillibridge, S. M. Ostroff, and J. M. Hughes. 2002. Public health assessment of potential biological terrorism agents. Emerg. Infect. Dis. 8:225-230.
28. Shapiro, E. D., L. A. Capobianco, A. T. Berg, and M. Q. Zitt. 1989. The immunogenicity of Haemophilus influenzae type B polysaccharide-Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children. J. Infect. Dis. 160:1064-1067.
29. Spink, W. W., J. W. I. Hall, J. Finstad, and E. Mallet. 1962. Immunization with viable Brucella organisms. Results of a safety test in humans. Bull. W. H. O. 26:409-419.
30. Stevens, T. L., A. Bosssie, V. M. Sanders, R. Fernandez-Botran, R. L. Coffman, T. R. Mossman, and E. S. Vitetta. 1988. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334:255-258.
31. Van De Verg, L. L., A. B. Hartman, A. K. Bhattacharjee, B. D. Tall, L. Yuan, K. Sasala, T. L. Hadfield, W. D. Zollinger, D. L. Hoover, and R. L. Warren. 1996. Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models. Infect. Immun. 64:5263-5268.
32. Vemulapalli, R. Y., Y. He, S. Cravero, N. Sriranganathan, S. M. Boyle, and G. G. Schurig. 2000. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect. Immun. 68:3286-3289.
33. Winter, A. J., G. G. Schurig, S. M. Boyle, N. Sriranganathan, J. S. Bevins, F. M. Enright, P. H. Elzer, and J. D. Kopek. 1996. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. Am. J. Vet. Res. 57:677-683.
34. Winter, A. J., G. E. Rowe, J. R. Duncan, M. J. Eis, J. Widom, B. Ganem, and B. Morein. 1988. Effectiveness of natural and synthetic complexes of porin and O-polysaccharide as vaccines against Brucella abortus in mice. Infect. Immun. 56:2808-2817.
35. Zollinger, W. D., J. Boslego, E. Moran, B. Brandt, H. Collins, R. Mandrell, P. Altieri, and S. Berman. November 1987. Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines. U.S. patent 4,707,543.